Compare Neurocrine Biosciences Inc (NBIX) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Noble Corporation plc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Noble Corporation plc trades at $40.19 (market cap $6.73B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× Noble Corporation plc's market cap, and Noble Corporation plc pays a 4.74% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Noble Corporation plc for 26 Days on average.
| NBIX | NE | |
|---|---|---|
Market Cap | $14.36B | $6.73B |
Volume | 1,237,180 | 1,027,635 |
Sector | Health | Energy |
52-Week High | $185.50 | $54.37 |
52-Week Low | $123.10 | $26.70 |
Typical Hold Time | 23 Days | 26 Days |
Enterprise Value | $14.37B | $8.16B |
Dividend Yield | — | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Noble Corporation (NE) trades at $40.97, down 1.16% today, with a bearish technical outlook. The stock shows mixed earnings performance with recent misses but maintains positive cash flow. Analyst consensus is divided with a $52 price target suggesting 27% upside. Recent news includes a long-term drilling contract with Tullow in Ghana, extending utilization into 2027.
The outlook remains cautious due to ongoing legal investigations and volatile earnings. While valuation appears reasonable with EV/EBITDA of 8.79, declining revenue and profit margins pose challenges. The dividend provides income support, but investors face execution risks amid mixed analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
